Eisenberg S P, Hale K K, Heimdal P, Thompson R C
Synergen Inc., Boulder, Colorado 80301.
J Biol Chem. 1990 May 15;265(14):7976-81.
Secretory leukocyte protease inhibitor (SLPI) is a two-domain protein that inhibits a wide range of proteases including chymotrypsin, leukocyte elastase, and trypsin. Based on its homology to other protease inhibitors and on x-ray crystallography of an SLPI-chymotrypsin complex it has been proposed that the elastase and chymotrypsin-inhibitory site is in the COOH-terminal domain and that the trypsin-inhibitory site is in the NH2-terminal domain. We have prepared muteins of SLPI by site-directed mutagenesis of a synthetic gene for the protein, followed by expression in Escherichia coli. The protease-inhibitory activities of these muteins indicate that leucine 72 in the COOH-terminal domain is at the inhibitory site for elastase and chymotrypsin. Unexpectedly, our measurements indicate that the trypsin-inhibitory site is not in the NH2-terminal domain. Instead they suggest that leucine 72 is also the inhibitory site for trypsin, even though the amino acid residues at the inhibitory sites of other trypsin inhibitors are almost always either lysine or arginine.
分泌型白细胞蛋白酶抑制剂(SLPI)是一种双结构域蛋白,可抑制多种蛋白酶,包括胰凝乳蛋白酶、白细胞弹性蛋白酶和胰蛋白酶。基于其与其他蛋白酶抑制剂的同源性以及SLPI - 胰凝乳蛋白酶复合物的X射线晶体学研究,有人提出弹性蛋白酶和胰凝乳蛋白酶抑制位点位于COOH末端结构域,而胰蛋白酶抑制位点位于NH2末端结构域。我们通过对该蛋白的合成基因进行定点诱变,随后在大肠杆菌中表达,制备了SLPI的突变体。这些突变体的蛋白酶抑制活性表明,COOH末端结构域中的亮氨酸72位于弹性蛋白酶和胰凝乳蛋白酶的抑制位点。出乎意料的是,我们的测量结果表明胰蛋白酶抑制位点不在NH2末端结构域。相反,它们表明亮氨酸72也是胰蛋白酶的抑制位点,尽管其他胰蛋白酶抑制剂抑制位点的氨基酸残基几乎总是赖氨酸或精氨酸。